If You Liked Part D, You'll Love Universal Coverage
This article was originally published in RPM Report
Executive Summary
It’s hard to say for sure how big a boost universal coverage would give to pharmaceutical companies’ bottom lines. But the industry’s most recent experience with expanded coverage in the key Medicare market offers some encouraging benchmarks for what to expect.